Company intelligence / Profile preview
SeaBeLife Biotech
- Ownership
- Private
- Employees
- ~15
- Development stage
- Preclinical
Overview
SeaBeLife has demonstrated compelling in vivo proof-of-concept in mouse models for both hepatotoxicity/liver injury and ocular pathologies. Their lead compounds have shown the ability to protect organs by blocking two forms of regulated cell death. IND-enabling studies are underway with plans to enter Phase I clinical trials in humans by early/mid–2025 for liver indications, and by early–2026 for geographic atrophy/dry AMD. The topical eye gel formulation has shown promising preclinical efficacy in delivering active ingredients to the retina[2][10].
- Therapeutic areas
- NephrologyGastroenterologyCardiovascularOphthalmologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on SeaBeLife Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SeaBeLife Biotech.